Coronavirus: EMA to submit Merck's anti-Covid drug to an ongoing review
Eva Deschamps / October 26, 2021
The European Medicines Agency EMA will submit the anti-Covid drug from U.S. pharmaceutical companies Merck and Ridgeback Bio to a continuing review, it announced Monday.
If the pill, called molnupiravir, gets the green light, it would be the first oral coronavirus drug to be approved.
The rolling review process allows the EMA to evaluate safety and efficacy data as they come in. Therefore, there is no need to wait for a formal application from the producer. The objective is to speed up the evaluation of an application if it is actually submitted.
The two companies themselves announced the results of the Phase 3 study earlier this month. The study appears to show that the treatment reduced the risk of hospitalization or death in the event of infection by half.
Related Posts
Omicron variant poses very high risk globally, says WHO
Sylvie Claire / November 29, 2021
The new Omicron variant of the coronavirus presents a very high risk at the global...
Read More
Coronavirus - Omicron: patients are not seriously ill for the moment
Sylvie Claire / November 28, 2021
People infected in South Africa with the new variant of the Omicron coronavirus ar...
Read More
The new variant of the coronavirus classified of concern by the WHO and named Omicron
Sylvie Claire / November 27, 2021
The new variant is now called Omicron. Experts mandated by the World Health Organ...
Read More